Therapeutic Area

Esophageal Squamous Cell Carcinoma

Therapeutic area intelligence for Esophageal Squamous Cell Carcinoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

oncology therapeutics →

Assets

Lactobacillus →

Phase →

Recent signals(2)

ClinicalJune 21, 2026

Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation

Lactobacillus reuteri induces D-lactate production, promoting STAT3 lactylation and reducing ferroptosis in ESCC.

ClinicalJune 19, 2026

Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer

A phase II trial is set to evaluate the efficacy and safety of intestinal low-dose radiotherapy combined with immunochemotherapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Esophageal Squamous Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.